The impact of metabolic control on cardiovascular outcomes in patients with type 2 diabetes and chronic multivessel coronary artery disease: a cohort study

代谢控制对2型糖尿病合并慢性多支冠状动脉疾病患者心血管结局的影响:一项队列研究

阅读:2

Abstract

BACKGROUD: The long-term impact of metabolic control on cardiovascular outcomes in patients with type 2 diabetes mellitus and stable coronary artery disease remains uncertain. While some studies suggest benefits from multifactorial interventions, data specifically evaluating sustained control of key metabolic parameters are limited. METHODS: From 884 patients enrolled between 1995 and 2010, 718 were selected. Data were analyzed from July 2022 to July 2024. Patients were categorized into four groups based on the number of metabolic factors within target range (low-density lipoproteins (LDL-C) < 100 mg/dL, glycated hemoglobin (HbA1C) < 7.5%, triglycerides < 150 mg/dL).  The primary outcome was a composite of all-cause mortality, myocardial infarction, stroke, and unplanned myocardial revascularization. Multivariate Cox regression models were calculated adjusting for confounders including age, sex, smoking, ejection fraction, number of diseased vessels, and initial coronary artery disease treatment. RESULTS: Of 718 patients (mean [SD] age, 61 [8] years; 254 female [35,3%]), followed during 8 (± 3.4) years, 199 (27.8%) had all 3 metabolic factors controlled, 260 (36.2%) had 2 factors controlled, 175 (24.3%) one factor controlled, and 84 (11.7%) no factor controlled. The group with all factors controlled was older and more frequently male. A dose-response association was observed, with progressively higher event rates as fewer metabolic factors were controlled. Patients with no controlled factors had nearly threefold the risk of events compared to those with all within target levels (HR 2.87, 95% CI 1.81-4.54, p < 0,01) in adjusted analysis. CONCLUSIONS: In patients with stable coronary artery disease and type 2 diabetes mellitus, inadequate control of metabolic factors was associated with higher risk of cardiovascular events over long-term follow-up. TRIAL REGISTRATION: Retrospectively registered.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。